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Abstract Human tissue biobanking encompasses a wide
range of activities and study designs and is critical for
application of a wide range of new technologies (-“omics”)
to the discovery of molecular patterns of disease and for
implementation of novel biomarkers into clinical trials.
Pathology is the cornerstone of hospital-based tissue bio-
banking. Pathologists not only provide essential information
identifying the specimen but also make decisions on what
should be biobanked, making sure that the timing of all
operations is consistent with both the requirements of clinical
diagnosisandtheoptimalpreservationofbiologicalproducts.
This document summarizes the conclusions of a Pathology
Expert Group Meeting within the European Biological and
Biomolecular Research Infrastructure (BBMRI) Program.
These recommendations are aimed at providing guidance for
pathologists as well as for institutions hosting biobanks on
This paper reflects the consensus of an expert working group of the
Biobank and Biomolecular Research Infrastructure program that met in
Munich on 17–18 December 2008. Authors are listed in alphabetical order
and participated equally to this working group. The last two authors, EC
and PH (IARC) convened the meeting and organized the manuscript.
G. Bevilacqua
Division of Surgical, Molecular and Ultrastructural Pathology,
University of Pisa and Pisa University Hospital, Medical School,
via Roma 57,
56126 Pisa, Italy
e-mail: g.bevilacqua@med.unipi.it
F. Bosman
Institut de Pathologie, CHUV,
Rue du bugnon 25,
1011 Lausanne, Switzerland
e-mail: Fred.Bosman@chuv.ch
T. Dassesse
European Organisation for Research and Treatment (EORTC),
Translational Research Unit,
Avenue E. Mounier, 83 b11,
1200 Brussels, Belgium
e-mail: thibaut.dassesse@gmail.com
H. Höfler
Institut für Allgemeine Pathologie und Pathologische Anatomie,
Der Technischen Universität München,
Ismaninger Str. 22,
81675 Munich, Germany
e-mail: hoefler@helmholtz-muenchen.de
A. Janin
Pathological Anatomy and Cytology, Saint Louis Hospital,
1 avenue Claude Vellefaux,
75475 Paris, France
e-mail: anne_janin@yahoo.com
R. Langer
Institute of Pathology, Klinikum Rechts der Isar,
Technische Universität München,
Trogerstrasse 18,
Munich 81675, Germany
e-mail: Rupert.Langer@lrz.tu-muenchen.de
D. Larsimont
Institut Jules Bordet, Service of Pathological Anatomy,
Cytology and Cytogenetics, Tumors Centre,
Rue Héger-Bordet 1,
1000 Brussels, Belgium
e-mail: denis.larsimont@bordet.be
M. M. Morente
Tumor Bank Unit, Molecular Pathology Program,
Spanish National Cancer Centre—CNIO,
Melchor Fernandez Almegro 3,
28029 Madrid, Spain
e-mail: mmorente@cnio.es
Virchows Arch (2010) 456:449–454
DOI 10.1007/s00428-010-0887-7how to better integrate and support pathological activities
within the framework of biobanks that fulfill international
standards.
Keywords Pathology.Biobanks.Biomarkers.
Harmonization.Standards.Translationalresearch
Introduction
Over the past 20 years, biobanking of human specimens has
become a central activity underpinning all aspects of bio-
medical research as well as the development of personalized
medicine [1–4]. Biobanking encompasses a wide range of
specimen types and sample collection designs, ranging from
population-based biobanking of specimens from healthy sub-
jects in large, epidemiological cohorts to specific biobanking
of diseased tissues obtained in the course of clinical inter-
ventions [2, 5–7]. Human tissue biobanking is of particular
importance for implementation of novel biomarkers into
clinical trials, as well as for the application of a wide range
of new technologies (-“omics”) to the discovery and
validation of new, molecular patterns of disease [8–12].
Heterogeneity and variability of pre-analytical practices is
a major source of error in analyzing biobanked specimens. In
recent years, large international efforts have converged
towards the harmonization of standard operating procedures
for biobanking, providing a basis for improving reproduc-
ibility and comparability of molecular data as well as for
designing large, multicentric studies involving specimen
exchanges among different centers [4, 13–17].
The most critical steps in the workflow of biospecimen
acquisition and annotation for biobanking involve hospital
pathologists. Pathology is the cornerstone of tissue bio-
banking.Themostbasic minimalstandardforanybiobanking
operation is to identify and define the nature and origin of the
tissues to be kept in the biobank. This requires specialized
pathology expertise. Furthermore, pathologists also make
decisions on what should be biobanked, making sure that the
timing of all operations is consistent with both the require-
ments of clinical diagnosis and the optimal preservation of
biologicalproducts. Pathologists alsoplay a central role inthe
design of studies involving banked biospecimens and in the
dialogue between clinicians and researchers. The rapid
development of biobanking as an essential process in
translationalresearchandpersonalizedmedicineplacesstrong
demands on the work of the pathologist.
ThisdocumentsummarizestheconclusionsofaPathology
Expert Group Meeting that took place in Munich in
December 2008 within the European Biological and Bio-
molecularResearchInfrastructure(BBMRI) Program[4, 18].
The experts have considered all aspects of the involvement
of the pathologist in the biobanking process. They also
discussed the impact of biobanking on pathology practice.
The recommendations developed in the document are aimed
at providing guidance for pathologists as well as for
institutions hosting biobanks on how to better integrate
and support pathological activities within the framework of
biobanks that fulfill international standards.
Scope and definition
1. The focus of the working group is the banking for
research of human tissues in a clinical context. This
activity is hereby defined as “tissue banking”.I t
includes, but is not limited to, the banking of residual
specimens obtained in the course of clinical procedures
as well as of “post-mortem material.”
2. Tissue banking is a chain of operations that includes
informing patients and obtaining the proper consent
(depending on local requirements), data acquisition,
tissue procurement, annotation, preservation, storage,
quality control, cataloguing, managing of access,
processing and distribution. Pathology expertise is
required at several steps. Tissue banking also requires
expertise in cryobiology, quality management, legal/
ethical aspects, project management, staff management,
administration and networking.
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repository that may support tissue banking, provided that
they fulfill required standards with respect to (1)
documentation of variations; (2) cataloguing; (3) rules
of access; (4) fulfillment of legal requirements for use as
researchresource.Theprimaryrole ofthesearchivesisto
document diagnosis and to support later/metachronous
diagnostic analyses but they should be developed in a
way that allows them to fulfill roles in research as well.
Recommendations
R1: The working group recommends developing a published reference
framework for “organizing and managing a tissue bank” in clinical
practice,defining standardsthatdistinguish“archive”from ‘tissuebank”.
R2: In the accreditation process of a pathology laboratory, the quality
and compliance to standard of the tissue archive/tissue banks must be
taken into consideration.
Tissue banking: critical role in articulating translational
research and personalized medicine
1. Tissue banking in a clinical context is essential for the
procurement of high quality samples for translational
research aimed at biomarker discovery and validation
as well as identification of new targets for therapy. It is
therefore a strategic activity for research and innovation
in biomedicine.
2. Tissue banking is critical for implementing and apply-
ing biomarkers in clinical practice. It lays the founda-
tions for the discovery of new targets for therapy and
for drug discovery. It sets conditions and procedures
allowing patients to benefit from new developments in
biomarkers as well as personalized medicine and is
therefore beneficial for future diagnosis and treatment
and for public health. In this vision, each patient
contributes to the care that will be provided to the
future patients.
3. Translational research on biomarkers encompasses
three overlapping phases: discovery, validation, and
implementation. Each phase has different requirements
in terms of tissue banking.
4. Discovery phase is aimed at identifying biomarkers and
molecular targets for therapy, establishing their preva-
lence and formulating hypotheses on their biological and
medical significance in ex vivo analyses. This requires
access to well annotated and pathologically reviewed
case series, either based on specimens collected and
processed in the course of clinical diagnostic activities or
in specific tissue collection protocols.
5. Validation phase is aimed at demonstrating the effect
and significance of a potential biomarker. This requires
applying ex vivo analyses within study designs with
adequate epidemiological and statistical power. Such
designs may be comparable to those of clinical trials
except that they do not necessarily imply de novo
specimen collection using invasive procedures. In a
number of cases, these studies can be constructed using
retrospective or prospective collections.
6. Implementation phase is aimed at translating biomarkers
into clinical practice in affordable, cost-effective con-
ditions and atintegrating new biomarkers into diagnostic
practice. This requires applying biomarkers to a large
series of specimens collected using standard operating
clinical protocols.
Recommendations
R3: Contributing to medical progress through participation in tissue
banking should be offered to the largest possible number of patients.
R4:Tissuebankingshouldtakeintoconsiderationtheneedforcollecting
appropriate reference samples. Whenever possible and appropriate, the
reference sample may consist of corresponding tissue not affected by the
disease process.
R5: Clinical practice should evolve to take into account the most
effective way to exploit new molecular validated biomarkers and
therapeutic targets. This requires technical innovation on evidence-
based protocols for tissue procurement, preservation and processing.
Innovation should also aim at better using archived collections.
R6: Given that specimens collected in clinical practice are critical for
research, rules of patient information and consent should be
compatible with the broad use of such specimens in conditions
fulfilling strict criteria of protection of persons and data. The working
grouprecommendsthatfurtherworkisdevelopedtoincreaseawareness
on these issues and to develop ethical and legal procedures at the
national and European level.
Role of the pathologist
1. The pathologist has an essential role in tissue banking.
His medical and scientific expertise is required at two
distinct phases in the process of tissue banking: (1) in
making diagnostic decisions, providing specific annota-
tions and overseeing specimen procurement and preser-
vation, and (2) in reviewing specimens and providing
informationpriortospecimenprocessinganddistribution
to research laboratories.
2. Throughhisroleintissuebanking,thepathologistisakey
actor inthe continuitybetweenresearchandmedicalcare.
3. The pathologist adds value and expertise to the defi-
nition of the banked tissue and is a critical scientific
contributor to research carried out on the specimen.
4. The pathologist validates the appropriateness of the
bankedtissuespecimenanditsuseforaparticularresearch
purpose, excluding conflicts with diagnostic purposes.
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specimens. Tissue collections are best developed in the
context of a pathology department or pathology service.
Recommendations
R7: No tissue banking for research should take place without proper
pathology documentation. All specimens used within research
programs must have been reviewed and assessed by a pathologist.
R8: The standard for tissue banking is a tissue sample and not derived
products or isolated molecules.
R9: The pathologist should have an active participation in decisions of
access to banked specimens.
R10:Effortsshouldbemadetobettercommunicatetheroleofpathology
in tissue banking.
Role of institutions
1. Tissue banking is not the exclusive responsibility of
pathology departments. It should be run in the context of
institutions (mainly hospitals or universities) that are
responsible for providing the whole chain of expertise
and the organizational frame required for tissue banking.
2. Institutions are responsible for the maintenance, sus-
tainability, and accessibility of tissue banks, adequate
level of training of the staff and the protection of
patient rights. Full cost calculation is an essential step
in guaranteeing the sustainability of the tissue bank.
Recommendations
R11: Institutions should commit adequate resources and staff
dedicated to acquisition, processing and proper distribution of both
data and specimens and assisting the pathologist in all tasks that do
not require a qualification in pathology. The basic requirements are (1)
daily and technical management, (2) data and specimen collection
management and (3) expertise in biobanking ethics and law, and (4)
networking biobanks. Biobank staff, depending on the size of the
pathology department should include at least a tissue bank manager
and a technician in addition to the pathologist. The institution should
commit adequate resources for pathologists to be involved, in addition
to their clinical task, in tissue-banking activities.
R12: Technical and pathology expertise should be provided by the
pathology department; the added scientific value should be recognized.
R13: Institutional commitment and appropriateness of the level of
resources dedicated to tissue banks should be considered as critical
elements in the process of tissue bank accreditation, which could be
part of a general hospital or pathology accreditation.
R14: The institution should be responsible for setting and publicizing
the rules of access to tissue banks.
R15: The rights of the patients should be taken into account in the
procedures and rules for access and use of the tissue bank.
R16: In granting access to tissue-banked specimens, a general principle
of “minimal sample amount of tissue necessary for the project” is
recommended.
R17: Each procurement of banked tissue for research should be formalized
through a Material Transfer Agreement (the scope and content of this
MTA is a matter for further elaboration at the European level).
R18: Funding agencies should be aware of the requirements of tissue
banking before granting funds for a research project. Projects using
banked specimens should specifically (1) provide assurance of the
participation and support of the tissue banks; (2) consider the costs of
specimen procurement and processing in relation with their specific
research application.
R19:AEuropeanframeworkfortheprofessionalizationoftissuebanking
should be developed, e.g., through a teaching program at master level.
Tissue banking in clinical trials
1. Clinical trials offer a wide range of designs with added
value for the discovery, validation and implementation
of potential new biomarkers
2. Using biomarkers is critical for the interpretation of
many therapeutic trials in particular for defining the
characteristics of responders vs. non-responders.
3. In future medical care, biomarkers will become manda-
tory for allocating patients to appropriate therapeutic
protocols.
4. The participation of a biobank into a clinical trial should
obey to the same strict technical, legal, and ethical
standards independently of the type of promoter, aca-
demic, or industrial.
Recommendations
R20: As a rule, tissue banking should be considered as an option in
every clinical trial.
R21: The need for biomarker application and the possibility of using
trials for biomarker validation should be taken into account in the
statistical and logistical design of the trial.
R22: Pathologists should be involved in trial design.
R23: There should be a comprehensive registry in the tissue bank
(ideally coupled to an institutional clinical trial registry system) of the
tissue samples collected in the context of clinical trials.
Improving standards for tissue banking
within clinical practice
1. There are technical differences in current standards for
tissue processing in pathology practice and in tissue
banking.
2. Many protocols used in tissue banking, e.g., for
duration of fixation, optimal time for preservation and
duration of storage, are mainly based on experience
rather than evidence.
3. There is a need for more adequate markers of quality for
thetissue-banking processforthequalificationof banked
tissue specimens for specific research applications.
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and therapeutic targets in the clinics require a very large
series of specimens with inter-laboratory comparison.
Such studies need strong networking between dedicated
platforms using harmonized, comparable protocols.
R24: Innovation in tissue banking should focus on reducing gaps
between standards for clinical practice and for research, and on the
development of biomarkers for the quality control of tissue-banking
procedures
R25: The development of evidence-based protocols supported by
published data should be a priority. Journal editors should be made
aware of this priority and should solicit contributions to support this
effort. Scientific journals should develop proper expert reviewing for
the correct collection, handling and processing of human tissues
forming the basis of published data.
R26: It is recommended that current European initiatives and
programs that develop technical platforms for large-scale specimen
analysis are duly reviewed, assessed, and “harvested” for developing
models for future network development.
Incentives for increasing the participation
of pathologists
1. Tissue banking is an important mechanism by which
pathologists participate in generating and increasing
knowledge in biomedicine.
2. In many instances, the involvement of the pathologist
adds scientific value to the banked specimens beyond
the requirements of routine diagnosis. This added value
corresponds to an intellectual property.
3. Tissue-banking activities entail considerable costs and
demands on pathology staff time.
R27: Efforts should be made to increase the awareness of the
pathology community that (1) participating in research through
tissue banking is part of their professional duties; (2) tissue banking
is an instrument for managing the evolution of pathology work
towards integration of biomarker analysis in clinical practice.
R28: Pathologists should be involved as scientists in developing the
design of studies using banked specimens and in interpreting their
results.
R29: The scientific involvement of pathologists should be acknowledged
in publication authorship. This involvement may consist of specific
diagnosticproceduresandannotationsatthetimeofspecimenacquisition
and/orpathologyreviewbeforespecimenprocessingforspecificresearch
purposes.
R30: Contributing to tissue banking should not compete with the
performance of clinical pathology duties; therefore, sufficient time and
resources should be committed by institutions to the performance of
tissue-banking activities.
R31: In developing research on banked specimens, researchers should
take into account the costs of the tissue-banking operation and should
include these costs in grant applications.
Conclusions and perspectives: a strategic vision
for tissue banking in Europe
Today, tissue banks have a key role in the process of
biomarker and drug target discovery through the procure-
ment of annotated specimens to innovative research
programs. In addition to this research role, the use of
cellular and molecular biomarkers is rapidly becoming a
standard part of hospital pathology practice and of thera-
peutic decision schemes. Tissue banking is the key
mechanism for pathologists to get involved in translating
newly discovered biomarkers into clinical practice [3].
Furthermore, tissue banking will rapidly become an
intrinsic part of pathology requirements in the context of
standard clinical care.
Given its strong linkage with clinical activities, tissue
banking is best performed at the local level, and its
sustainability requires investment in infrastructure at the
local and/or regional and national levels, to avoid duplica-
tion of effort and achieve critical mass necessary to address
major academic research programs, as well as to secure a
strong position in addressing the needs of industry.
Therefore, tissue banks must be organized in operational
networks [18].
Implementation of biomarkers will require large networks
interconnecting tissue banks, analysis and distribution plat-
forms and several other data resources such as databases of
clinical information and population-based disease registries.
Biobank networks should have fully documented standard
operating procedures, share tissue bank catalogues, and clear
rules for access [19–21]. They should also be able to run
research projects based on collections developed in several
tissue banks. Such projects may be retrospective (using
previously banked specimens) or prospective. Running the
same, hypothesis-driven collection protocol through a large
network of tissue banks that adhere to the same standards
will allow assembling large case series addressing a wide
range of clinical conditions. In developing such protocols,
the diversity of European populations and ecological
contexts is an asset for the design of sophisticated case–
case comparison studies [22].
To achieve this vision, it is essential to perform
innovative research on improving all aspects of specimen
processing, including the development of quality controls
applicable to retrospective collections. This requires a
dedicated effort from funding agencies and from the
scientific and medical publication community. Training of
highly qualified tissue-banking professionals will increase
the standards of tissue banking as well as the recognition
of tissue banking as an integral part of biomedicine. This
will also facilitate the development and dissemination of
a corpus of harmonized, evidence-based tissue-banking
procedures.
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